BlueTech Media’s Post

We're thrilled to announce Dr. Kunal Joshi, Head of Marketing, Cell & Gene Therapy - CAR T, Dr. Reddy's Laboratories as our Esteemed Speaker for the 4th Edition of the India Biopharma Leaders Conclave, hosted by BlueTech Media™. Together, we're set to embark on a journey to explore "New Horizons in Biopharma, Biosimilars, & Biologics"! 🚀 . Date: 13th & 14th June, 2024, Hyderabad To Register for the event click https://lnkd.in/d2T9iruW . This year's theme promises a deep dive into the latest advancements shaping the biopharmaceutical landscape, with a spotlight on the exciting realms of biosimilars and biologics. With renowned speakers and eminent leaders from around the globe, this event is set to be a beacon of knowledge and innovation. . Why Attend: 🔍 Gain valuable insights into industry evolution, regulatory changes, and compliance challenges. 🤝 Expand your professional network by connecting with industry peers and potential collaborators. 💡 Discover cutting-edge products, services, and technologies driving biopharma innovation. 🔄 Engage in meaningful discussions to shape the future trajectory of the industry. 🔬 Explore challenges and opportunities, from regulatory hurdles to ethical considerations. . Event Highlights: 🎤 40+ Speakers 🤝 200+ Delegates 🤝 4+ Associations 📰 4+ Media Partners 🤝 15+ Partners . Key Topics Include: 🔬 The future and challenges of biosimilars 🔬 Success rates and challenges in biosimilar R&D 🔬 Quality, safety, and efficacy standards in biosimilars 🔬 Future of cell and gene therapy manufacturing 🔬 Emerging trends in quality assurance for biologics 🔬 Digitalized supply chains in biopharma 🔬 The crucial role of a digital backbone in the industry 🔬 Advances and barriers in CAR-T cell therapies Don't miss this opportunity to be at the forefront of biopharmaceutical innovation! . #Bluetechmedia #IndiaBiopharmaLeadersConclave #pharmaevents #pharmaceutical #Corporate #PharmaEvents #PharmaConferences #PharmaConclave #PharmaLeaders #BlueTechMedia #BiopharmaLeaders #Innovation #Biosimilars #Biologics #IndustryInsights

“Bioassays: The Tiny Giants of Biopharmaceutical Innovation” Bioassays are often tiny components in the vast landscape of biopharmaceutical drug development, but their impact is monumental. Developing and validating bioassays—especially for biosimilars—can be an intricate puzzle. When it comes to vaccines and cell & gene therapies (CGT), the complexity rises exponentially. Here, bioassay development transforms into a delicate art—a blend of precision, creativity, and scientific rigor. At Biologics 2025, we are diving deep into this art. Moderated by Dr. Nimesh GUPTA (NII), the session will feature few exceptional minds: Debaditya Bhattacharya, Ph.D. Claudia Lin Amit Awasthi Dan Mamelak, PhD Together, they will unravel bioassay challenges, strategies, and insights across diverse therapeutic modalities—promising an engaging and thought-provoking discussion. Join us as we explore how these “tiny giants” drive innovation and enable breakthrough treatments in biologics, vaccines, and CGT. Biologicsworkshop.com 📅 January 30-31, 2025 | Goa Register here: https://lnkd.in/grvy24QP Let’s celebrate the art and science of bioassays together. #Biologics2025 #Bioassays #Biopharmaceuticals #CGT #Vaccines #Innovation #biosimilars Biologics Workshop Mumbai Biocluster Prajakta Dandekar Anushka Chaudhari Preeti Kaushik Jaidev Bhatt Vishakha Kurlawala Saurabh Kale Sanyukta Katoch Astra Dsouza TEJAL KHANNA Neha Gupta

The Good, The Bad, The Ugly: Biotech Edition, May 20 - 23 Featuring AstraZeneca’s monster revenue ambitions, Biogen says bye to $1.15B, more AI drug discovery collabs, and Novo Nordisk is on fire (again). The Good Robo-play; Astellas gets curious about automated cell therapy manufacturing robot 🤖https://bit.ly/3ytpcZI Double or nothing; AstraZeneca aims for $80B in revenue by 2023 🤑 https://bit.ly/3ynVpS3 ROI; Gilead’s $4.3B CymaBay acquisition approaches payday after posting positive Ph3 data 💰 https://bit.ly/3V90CGr Open Formation; Sanofi, OpenAI, Formulation Bio AI collab 💻 https://bit.ly/3WUWQlc HI there; Biogen buys HI-Bio for $1.15B 🤝 https://bit.ly/3V8Dk3s The Bad What the Hel; Helsinn’s accelerated approval yanked by FDA ❌ https://bit.ly/3ynVq8z “Strategic exit”; Evotec shutters gene therapy division 🧬 https://bit.ly/3WXS72p Agitating failure; Otsuka ditches Alzheimer’s med after Ph3 failure 👎 https://bit.ly/3VbEeft Exsciential crisis? AI-powered drug developer cuts staff, 20-25% 😢 https://bit.ly/4bO0r8P The Ugly Again? Another Novo Nordisk site fire 🤕 https://bit.ly/3ynVqFB Too much of a good thing? Novo Nordisk’s once-weekly insulin may cause hypoglycemia 🍬 https://bit.ly/3wBpFIV GSK feeling the burn; lawsuit alleges they knew about Zantac cancer risk for decades ⚖️ https://bit.ly/3ytpdNg Explain this; Senate grills Pfizer on “incomprehensibly…lower tax rate” 😬 https://bit.ly/3WUAYqk —————————— Comprehensive, daily coverage of the biotech and pharma industry, straight to your inbox and all in one email - that's TLDR Biotech. 🧬🔔 It’s free to subscribe - link in the comments ⬇️ #pharmanews #biotechnews #tldrbiotech #goodbaduglybiotech

Very interesting issue of PHARMAnetwork stressing the increasing role of CDMOs in drug development and manufacturing with a projected 25% revenue increase in the next 2 years. 👉 CDMOs play an important role in the early-stage development activities of biotech start-ups. Establishing strategic partnerships combining the innovation and agility of biotech firms with the expertise, efficiency, and scalability of CDMOs is key for bringing new and effective therapies to market efficiently and cost-effectively. 👉 Early interactions in the drug development life cycle is essential for CDMOs to build sustainable growth and financially stable businesses and key for emerging biotech to build solid CMC foundations as they scale. 👉 CDMOs also play a crucial role in providing increased manufacturing capabilities for large pharma as illustrated by the strategic partnerships established by Moderna with Lonza and Catalent Pharma Solutions to supply high vaccins demand during COVID-19 or more recently by the planned acquisition of Catalent Pharma Solutions by Novo Holdings to remediate Novo Nordisk supply issues after the launch of Wegovy. 👉 High demand for sterile manufacturing capabilities is a lasting trend with the sterile pharmaceutical market expected to grow by more than 50 percent over the next seven years. 👍 Strategic partnerships between pharma/biotech and CDMOs are mutually beneficial. They enable pharma companies to accelerate drug development and to face increasing commercial manufacturing demand for innovative drugs, generics and biosimilars and they support CDMOs sustainable growth and investments in new technology platforms and manufacturing capabilities.

Discover the April 2024 issue of PHARMAnetwork magazine:   Cell and gene therapies: between hopes and uncertainty Since 1997 and the first launch of these products, the development of cell and gene therapies has increased rapidly and raised more and more funding. Despite a promising outlook and growing interest from companies, uncertainty remains on the commercial viability of products that serve small patient populations. Questions and answers with the latest report by IQVIA Institute   CDMO: Opportunities and challenges in a market disrupted by obesity therapies and regulations The success of CDMOs will depend on their ability to innovate in disrupted situations and to comply with changing regulatory environments (Inflation Reduction Act, Biosecurity Act, etc.), while navigating their way through the economic pressures of the pharmaceutical industry. It is essential to understand the landscape these entities operate in, as well as the external factors impacting them.   Conquering The Latest Demand: From COVID-19 vaccines to GLP-1s, Grand River Aseptic Manufacturing invests to ensure clients receive superior fill-finish services   Termination and transfer clauses in Manufacturing and Supply Agreements (MSA): What are the key points? How best to manage the termination or transfer of an MSA, without exposing the parties to the risk of claims that could prove very costly?   A Strategic Approach to Cost in Biopharma Manufacturing costs are rising rapidly, with no end in sight. Leaders that balance the various tradeoffs can remain competitive over the long run.   https//:www.pharmanetwork.digital   BSP Pharmaceuticals S.p.A., giorgio salciarini Grand River Aseptic Manufacturing, Chelsea Keeton, Tom Ross FAREVA, Alexandre Bastit, Patrice Meslier, Julie FERRARIS NextPharma, Pierre Delavaud, Catherine Cornille PHARMATIS, Pierre BANZET, PCI Pharma Services, Tania Moorehead, Katie Jones, Jerome Detreille Lonza Catalent Pharma Solutions, Bastien Cotte, Aurélien GAILLARD Nathalie CAZEAU Unither Pharmaceuticals, Marc Maury, Elisabeth A., Eric Chesnel Arnaud Hanquez   #pharmaceutical #CDMO #Biotech #pharmanetwork

🤳 𝐂𝐃𝐌𝐎 𝐌𝐚𝐫𝐤𝐞𝐭 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 💼 Lonza Introduces “One Lonza” Strategy, Exiting CHI Business Lonza unveils its “One Lonza” strategy, focusing on its CDMO sector while planning to exit the Capsules & Health Ingredients (CHI) business by 2025. This strategic move aligns with its goal of becoming a pure-play CDMO. CEO Wolfgang Wienand emphasizes its aim to enhance customer and shareholder value through streamlined operations. 🌐 SK pharmteco Unifies Global Operations Under One Brand SK pharmteco consolidates its global network, including SK biotek, AMPAC Fine Chemicals, and Yposkesi, into a single entity. The unified brand offers seamless, end-to-end pharmaceutical and cell and gene therapy solutions, strengthening its position as a global CDMO leader. ⚛️ NorthStar Medical Radioisotopes, LLC Secures Actinium-225 Supply Agreement with Ariceum Therapeutics NorthStar Medical Radioisotopes partners with Ariceum Therapeutics to supply high-purity Actinium-225 (Ac-225), a critical isotope for advancing radiopharmaceutical cancer treatments. This agreement supports Ariceum’s pipeline innovation in targeted therapies. 🏢 Scinai Immunotherapeutics Ltd. Immunotherapeutics Launches U.S. Subsidiary for CDMO Services Scinai Bioservices Inc. opens to address the demand for early-stage biotech CDMO services in the U.S. The subsidiary supports startups with U.S. grant funding, enabling them to access CDMO services while aligning with BIOSECURE Act compliance. 🔨 Novo Nordisk to Invest $1.2 Billion in New Denmark Facility Novo Nordisk announces its largest Danish investment in decades with the construction of a new production facility in Odense. The 40,000 m² site will support rare disease products and create 400 permanent jobs post-completion in 2027. 💉 Cellipont Bioservices and Xiogenix Team Up to Revolutionize Fill-Finish Processes Cellipont Bioservices adopts the Xiogenix Ares X20 fill-and-finish system to enhance precision in cell therapy manufacturing. The advanced system offers automated formulation, temperature control, and efficient throughput, ensuring consistent, high-quality results. Apsida Life Science #CDMO #News #UpToDate

🌶 𝐃𝐚𝐢𝐥𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐃𝐢𝐠𝐞𝐬𝐭 (May 28, 2024) 👇 💊Novartis: Planning regulatory submissions for rare kidney diseases this year. 🧪Johnson & Johnson: Acquired Numab Therapeutics AG Therapeutics’ bispecific antibody NM26 for Phase II studies. 🧬Innovent Biologics: Achieved primary endpoints in Phase 3 trial for moderate to severe plaque psoriasis. 💡RevolKa Ltd.: Signed a master service agreement with Daiichi Sankyo US for protein engineering technology. 🦠Moderna: Reported smaller-than-expected loss for Q1 due to strong Covid vaccine sales. 🔬Merck Group: Acquired gene therapy tools maker for $600 million. 🧫Biogen: Acquired immune drugmaker HI-Bio for $1.15 billion. 🏭Eli Lilly and Company: Invested an additional $5.3 billion in its Indiana plant. 🎯AstraZeneca: Set a sales target of $80 billion by 2030. 🤝Novavax: Experienced a significant turnaround following its partnership with Sanofi. 📉 LOSERS: 🤷♀️AstraZeneca: Failed to show overall survival benefit in non-small cell lung cancer patients. 🚫 Novo Nordisk: FDA Ad-com voted against Icodec once-weekly insulin in Type1 diabetes, 7-4 💰Pfizer: Plans to save $1.5 billion by 2027 through cost-cutting measures. What are your thoughts on these developments? Share your insights below! Don't forget to follow ATACANA GROUP Inc. for daily updates on Pharma winners and losers! #pharmaceuticals #biotech #news #artificialintelligence #competitiveintelligence

OCYONBIO Presents at Biomap Consortium Industry Day April 5-2024 Excited to share insights from our recent presentation at the BioMaP Consortium Industry Day held at the Strategic Analysis Executive Conference Center in Arlington, VA. OcyonBio has demonstrated its dedication to shaping the biomanufacturing landscape through innovation and strategic partnerships. 🔬 Company Mission At OcyonBio, we're not just about developing cutting-edge technology; we're making life-saving therapies accessible. Our 200,000 sq. ft facility is equipped with the latest in R&D suites, gene therapy capabilities, and continuous manufacturing processes essential for the next generation of therapeutics. 💡 Capabilities Spotlight We're at the forefront of biologics, with competencies spanning from bacterial and mammalian drug substances to vials and cartridges for drug products. Our expertise in cell and gene therapy is marked by our advanced viral vector manufacturing and clinical-scale solid dosage capabilities, including direct compression and granulation. 🤝 Building Partnerships The BioMaP Consortium Industry Day was an excellent platform for us to showcase our commitment to fostering collaborations that drive innovation. By connecting with government entities and other industry leaders, we've reinforced our goal to expand the biopharmaceutical manufacturing sector's capabilities. 🚀 Future-Forward Approach Our presentation highlighted how OcyonBio's expansion into sterile manufacturing, supported by our partnership with Marchessini, bolsters our mission to be at the forefront of the industry. This expansion is a testament to our ability to meet the dynamic needs of the market and deliver quality, efficiency, and innovation. We are proud to be part of a consortium that's dedicated to preparedness and response for public health emergencies. By advancing biomanufacturing technologies, we ensure a resilient future for the healthcare sector. 🔗 For more on our capabilities and offerings, visit OcyonBio.com. Join the conversation on how we can further innovate and collaborate within the biopharmaceutical manufacturing industry! #OcyonBio #BioMaPConsortium #Biomanufacturing #PublicHealth #Innovation #Partnership #GeneTherapy #BARDA

Amid global economic uncertainties and challenges in biotech, the APAC region stands tall as a resilient and promising market for clinical trials. Whether you're an emerging biopharma innovator or technology provider, our 3rd Clinical Trials Festival Asia (CTFA) 2025 in Singapore connects you with world-class industry leaders in Biologics, Cell & Gene Therapy, and Vaccines. CTFA 2025 will be held on 12th-13th March under one roof with: ⚗️12th Biologics Manufacturing Asia 🚚 9th Biologistics World Asia 🌐 2nd Biologics Digitalization and AI World 💉Antibody-Drug Conjugate Asia Congress Expect insights from 300+ attendees, 150+ companies, and 30+ experts, with opportunities to engage top leaders, explore tailored solutions, and network at the Asia-Pacific Biopharma Excellence Awards Gala. 🔗 Discover who’s attending and get insights—Download the 2024 attendee list and post-event report! https://lnkd.in/gCBhYSXG #ClinicalTrials #Biopharma #CRO #CellandGeneTherapy #APACInnovation #Biologics #Vaccines

The role of CDMOs is evolving, driven by market opportunities and the demand for breakthrough therapies such as cell and gene therapies, mRNA treatments, and innovative vaccines. These advancements require innovative manufacturing capabilities, pushing CDMOs to lead in this landscape.